VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and certain CNS disorders where current treatments are believed by VistaGen to be inadequate, resulting in high unmet need. Each of VistaGen's three drug candidates has a differentiated mechanism of action, an exceptional safety profile, and therapeutic potential in several large global CNS markets.
Ticker:
VTGN
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
PH94b Neuroactive Nasal Spray
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
